Trial Profile

A clinical study investigating the safety and efficacy of PXT3003 for CMT1A in children.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baclofen/naltrexone/sorbitol (Primary)
Indications Charcot-Marie-Tooth disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Jan 2019 According to a Pharnext media release, the company is planning to initiate a Phase 3 trial with pediatric PXT3003 by the end of 2019.
16 Jul 2018 New trial record
10 Jul 2018 According to a Pharnext media release, the European Medicines Agency (EMA) has agreed with its pediatric investigation plan (PIP) for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com